Onconova Therapeutics, Inc. – NASDAQ:ONTX
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 4 hours
Onconova Therapeutics stock price monthly change
+45.89%
month
Onconova Therapeutics stock price quarterly change
+25.95%
quarter
Onconova Therapeutics stock price yearly change
+36.17%
year
Onconova Therapeutics key metrics
Market Cap | 20.90M |
Enterprise value | N/A |
P/E | -0.76 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 41.51 |
Price/Book | 0.49 |
PEG ratio | -0.14 |
EPS | -0.87 |
Revenue | 226K |
EBITDA | -19.36M |
Income | -18.15M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -7997.05% |
Oper. margin | -8223.89% |
Gross margin | 0% |
EBIT margin | -8223.89% |
EBITDA margin | -8566.37% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOnconova Therapeutics stock price history
Onconova Therapeutics stock forecast
Onconova Therapeutics financial statements
| Jun 2023 | 57K | -4.25M | -7456.14% |
|---|---|---|---|
| Sep 2023 | 57K | -4.73M | -8314.04% |
| Dec 2023 | 56K | -4.18M | -7471.43% |
| Mar 2024 | 56K | -4.98M | -8898.21% |
| 2025 | 300K | -28.4M | -9466.67% |
|---|---|---|---|
| 2026 | 300K | -33M | -11000% |
| 2027 | 300K | -19.93M | -6646.47% |
| 2028 | 400K | -24.34M | -6086.77% |
Analysts Price target
Financials & Ratios estimates
| 2023-05-15 | -0.3 | -0.2 |
|---|
| Jun 2023 | 30468000 | 11.57M | 37.97% |
|---|---|---|---|
| Sep 2023 | 27038000 | 12.52M | 46.31% |
| Dec 2023 | 22683000 | 12.01M | 52.95% |
| Mar 2024 | 18172000 | 12.15M | 66.9% |
| Jun 2023 | -4.49M | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -4.46M | -14K | 0 |
| Dec 2023 | -4.43M | -13.99B | 0 |
| Mar 2024 | -4.42M | 0 | 0 |
Onconova Therapeutics alternative data
| Aug 2023 | 16 |
|---|---|
| Sep 2023 | 16 |
| Oct 2023 | 16 |
| Nov 2023 | 16 |
| Dec 2023 | 16 |
| Jan 2024 | 16 |
| Feb 2024 | 16 |
| Mar 2024 | 16 |
| Apr 2024 | 16 |
| May 2024 | 16 |
| Jun 2024 | 16 |
| Jul 2024 | 16 |
Onconova Therapeutics other data
2.17%
-5.25%
of ONTX is owned by hedge funds
14
-11
453.27K
-1.09M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2021 | 85000 | 0 |
| Sep 2021 | 13095 | 0 |
| Nov 2021 | 1000 | 0 |
| Jan 2022 | 6000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | GUERIN MARK PATRICK officer: CFO AND COO | Common Stock | 6,900 | N/A | N/A | ||
Option | GUERIN MARK PATRICK officer: CFO AND COO | Restricted Stock Units | 6,900 | N/A | N/A | ||
Option | FRUCHTMAN STEVEN M director, officer.. | Common Stock | 21,320 | N/A | N/A | ||
Option | FRUCHTMAN STEVEN M director, officer.. | Restricted Stock Units | 21,320 | N/A | N/A | ||
Option | GUERIN MARK PATRICK officer: CFO AND COO | Common Stock | 4,750 | N/A | N/A | ||
Option | GUERIN MARK PATRICK officer: CFO AND COO | Restricted Stock Units | 4,750 | N/A | N/A | ||
Option | FRUCHTMAN STEVEN M director, officer.. | Common Stock | 12,567 | N/A | N/A | ||
Option | FRUCHTMAN STEVEN M director, officer.. | Restricted Stock Units | 12,567 | N/A | N/A | ||
Option | GUERIN MARK PATRICK officer: CFO AND COO | Common Stock | 5,500 | N/A | N/A | ||
Option | GUERIN MARK PATRICK officer: CFO AND COO | Restricted Stock Units | 5,500 | N/A | N/A |
| Patent |
|---|
Application 8-CYCLOPENTYL-7-OXO-2-(4-PIPERAZIN-1-YL-PHENYLAMINO)-7, 8-DIHYDRO-PYRIDO [2,3-D]PYRIMIDINE-6-CARBONITRILE AND USES THEREOF IN TREATING PROLIFERATIVE DISORDERS Filling date: 12 Nov 2018 Issue date: 6 Jan 2022 |
Application FORMULATION OF (E)-2,4,6-TRIMETHOXYSTYRYL-3-[(CARBOXYMETHYL)AMINO]-4-METHOXYBENZYLSULPHO- NE WITH ENHANCED STABILITY AND BIOAVAILABILITY Filling date: 13 Apr 2018 Issue date: 24 Jun 2021 |
| Quarter | Transcript |
|---|---|
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 15 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 16 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Steven M. Fruchtman (1951) Chief Executive Officer, Pres & Director | $865,440 |
Mr. Mark Patrick Guerin CPA (1969) Chief Financial Officer | $512,190 |
-
When is Onconova Therapeutics's next earnings date?
Unfortunately, Onconova Therapeutics's (ONTX) next earnings date is currently unknown.
-
Does Onconova Therapeutics pay dividends?
No, Onconova Therapeutics does not pay dividends.
-
How much money does Onconova Therapeutics make?
Onconova Therapeutics has a market capitalization of 20.90M. Onconova Therapeutics made a loss 18.95M US dollars in net income (profit) last year or -$0.2 on an earnings per share basis.
-
What is Onconova Therapeutics's stock symbol?
Onconova Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ONTX".
-
What is Onconova Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Onconova Therapeutics?
Shares of Onconova Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Onconova Therapeutics's key executives?
Onconova Therapeutics's management team includes the following people:
- Dr. Steven M. Fruchtman Chief Executive Officer, Pres & Director(age: 74, pay: $865,440)
- Mr. Mark Patrick Guerin CPA Chief Financial Officer(age: 56, pay: $512,190)
-
How many employees does Onconova Therapeutics have?
As Jul 2024, Onconova Therapeutics employs 16 workers.
-
When Onconova Therapeutics went public?
Onconova Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 25 Jul 2013.
-
What is Onconova Therapeutics's official website?
The official website for Onconova Therapeutics is onconova.com.
-
Where are Onconova Therapeutics's headquarters?
Onconova Therapeutics is headquartered at 12 Penns Trail, Newtown, PA.
-
How can i contact Onconova Therapeutics?
Onconova Therapeutics's mailing address is 12 Penns Trail, Newtown, PA and company can be reached via phone at +267 7593680.
Onconova Therapeutics company profile:
Onconova Therapeutics, Inc.
onconova.comExchange:
NASDAQ
Full time employees:
16
Industry:
Biotechnology
Sector:
Healthcare
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
12 Penns Trail
Newtown, PA 18940
Newtown, PA 18940
CIK: 0001130598
ISIN: US68232V8019
CUSIP: 68232V801
